Martine Amiot

List of Publications by Year
in descending order

79 papers	5,186 citations	87723 38 h-index	88477 70 g-index
79 all docs	79 docs citations	79 times ranked	6122 citing authors

#	Article	IF	Citations
1	Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes. Cell Death and Disease, 2020, 11, 316.	2.7	31
2	The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma. BMC Cancer, 2019, 19, 855.	1.1	5
3	Targeting Oxidative Stress With Auranofin or Prima-1Met to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells. Frontiers in Oncology, 2019, 9, 128.	1.3	14
4	CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages. Leukemia, 2019, 33, 2442-2453.	3.3	45
5	Disruption of IRE1Î± through its kinase domain attenuates multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16420-16429.	3.3	78
6	The selectivity of Marinopyrrole A to induce apoptosis in <scp>MCL</scp>1^{high}<scp>BCL</scp>2^{low} expressing myeloma cells is related to its ability to impair protein translation. British Journal of Haematology, 2018, 180, 157-159.	1.2	6
7	Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways. Journal of Hematology and Oncology, 2018, 11, 137.	6.9	36
8	BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. Blood, 2018, 132, 2656-2669.	0.6	57
9	p53 regulates CD46 expression and measles virus infection in myeloma cells. Blood Advances, 2018, 2, 3492-3505.	2.5	17
10	Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia, 2018, 32, 1899-1907.	3.3	109
11	Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells. International Journal of Molecular Sciences, 2018, 19, 40.	1.8	1
12	BCL2-Family Dysregulation in B-Cell Malignancies: From Gene Expression Regulation to a Targeted Therapy Biomarker. Frontiers in Oncology, 2018, 8, 645.	1.3	53
13	S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget, 2018, 9, 20075-20088.	0.8	82
14	Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). Haematologica, 2017, 102, e112-e114.	1.7	43
15	p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. Blood Reviews, 2017, 31, 251-259.	2.8	47
16	Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood, 2017, 130, 2401-2409.	0.6	403
17	Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax. Cancer Discovery, 2017, 7, 1376-1393.	7.7	105
18	Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 767-779.	1.5	62

#	Article	IF	Citations
19	<scp>BH</scp>3 profiling as a tool to identify acquired resistance to venetoclax in multiple myeloma. British Journal of Haematology, 2017, 179, 684-688.	1.2	26
20	The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma. BMC Cancer, 2016, 16, 802.	1.1	7
21	Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood, 2016, 128, 2808-2818.	0.6	78
22	Repression of Mcl-1 and disruption of the Mcl-1/Bak interaction inÂmyeloma cells couple ER stress to mitochondrial apoptosis. Cancer Letters, 2016, 383, 204-211.	3.2	22
23	BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. Journal of Experimental Medicine, 2016, 213, 1705-1722.	4.2	24
24	The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1Â inhibition in myeloma cells. Haematologica, 2016, 101, e107-e110.	1.7	11
25	Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Molecular Cancer Therapeutics, 2016, 15, 1132-1144.	1.9	231
26	Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study. Blood, 2016, 128, 488-488.	0.6	27
27	A simple flow cytometryâ€based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2015, 87, 285-288.	1.1	16
28	Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups. Cancer Biology and Therapy, 2015, 16, 60-65.	1.5	22
29	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results. Blood, 2015, 126, 4219-4219.	0.6	11
30	Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Oncotarget, 2015, 6, 8750-8759.	0.8	70
31	Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma. Oncotarget, 2015, 6, 26922-26934.	0.8	29
32	The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma. Leukemia, 2014, 28, 210-212.	3.3	244
33	Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK. Cell Death and Disease, 2014, 5, e1389-e1389.	2.7	11
34	Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. Leukemia and Lymphoma, 2014, 55, 2165-2173.	0.6	20
35	RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53 abnormal myeloma cells independently of the p53 pathway. BMC Cancer, 2014, 14, 437.	1.1	19
36	PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance. Blood, 2014, 124, 1626-1636.	0.6	134

#	Article	IF	Citations
37	Hypoxia-inducible factor (HIF)-1Î± suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. Leukemia, 2013, 27, 1697-1706.	3.3	104
38	Apoptotic Machinery Diversity in Multiple Myeloma Molecular Subtypes. Frontiers in Immunology, 2013, 4, 467.	2.2	24
39	Cereblon expression in multiple myeloma: not ready for prime time. British Journal of Haematology, 2013, 163, 282-284.	1.2	18
40	Lack of BRAF V600E mutation in human myeloma cell lines established from myeloma patients with extramedullary disease. Blood Cancer Journal, 2013, 3, e163-e163.	2.8	6
41	Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma. British Journal of Cancer, 2013, 108, 1801-1806.	2.9	16
42	Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells. Blood Cancer Journal, 2013, 3, e120-e120.	2.8	22
43	Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells. Cancer Research, 2012, 72, 4562-4573.	0.4	58
44	Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Blood Cells, Molecules, and Diseases, 2012, 48, 247-253.	0.6	24
45	The cap-translation inhibitor 4EGI-1 induces apoptosis in multiple myeloma through Noxa induction. British Journal of Cancer, 2012, 106, 1660-1667.	2.9	46
46	The peripheral CD138⁺ population but not the CD138^{âˆ'} population contains myeloma clonogenic cells in plasma cell leukaemia patients. British Journal of Haematology, 2012, 156, 679-683.	1.2	25
47	Noxa controls Mule-dependent Mcl-1 ubiquitination through the regulation of the Mcl-1/USP9X interaction. Biochemical and Biophysical Research Communications, 2011, 413, 460-464.	1.0	71
48	TLR9 Ligand Induces the Generation of CD20+ Plasmablasts and Plasma Cells from CD27+ Memory B-Cells. Frontiers in Immunology, 2011, 2, 83.	2.2	25
49	A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica, 2011, 96, 574-582.	1.7	141
50	ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood, 2011, 118, 3901-3910.	0.6	106
51	ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2<i>high</i>/Mcl-1<i>low</i> Profile and Synergizes with Other Antineoplastic Agents. Clinical Cancer Research, 2011, 17, 5973-5981.	3.2	50
52	Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma. Leukemia, 2011, 25, 872-874.	3.3	56
53	Mclâ€‘1^{128â€“350} fragment induces apoptosis through direct interaction with Bax. FEBS Letters, 2010, 584, 487-492.	1.3	12
54	BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma. British Journal of Cancer, 2010, 103, 1808-1814.	2.9	28

#	Article	IF	Citations
55	The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma. British Journal of Haematology, 2009, 145, 180-189.	1.2	22
56	TLR3 Ligand Induces NF-Î°B Activation and Various Fates of Multiple Myeloma Cells Depending on IFN-Î± Production. Journal of Immunology, 2009, 182, 4471-4478.	0.4	59
57	IL-21 Stimulates Human Myeloma Cell Growth through an Autocrine IGF-1 Loop. Journal of Immunology, 2008, 181, 6837-6842.	0.4	40
58	Noxa Up-regulation and Mcl-1 Cleavage Are Associated to Apoptosis Induction by Bortezomib in Multiple Myeloma. Cancer Research, 2007, 67, 5418-5424.	0.4	210
59	Reciprocal protection of Mcl-1 and Bim from ubiquitin-proteasome degradation. Biochemical and Biophysical Research Communications, 2007, 361, 865-869.	1.0	26
60	Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells. European Cytokine Network, 2007, 18, 120-6.	1.1	23
61	Mcl-1L cleavage is involved in TRAIL-R1â€" and TRAIL-R2â€"mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood, 2006, 108, 1346-1352.	0.6	59
62	CD45neg but Not CD45pos Human Myeloma Cells Are Sensitive to the Inhibition of IGF-1 Signaling by a Murine Anti-IGF-1R Monoclonal Antibody, mAVE1642. Journal of Immunology, 2006, 177, 4218-4223.	0.4	33
63	The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica, 2006, 91, 1234-40.	1.7	159
64	Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex. Oncogene, 2005, 24, 8076-8079.	2.6	62
65	Endogenous association of Bim BH3-only protein with Mcl-1, Bcl-xL and Bcl-2 on mitochondria in human B cells. European Journal of Immunology, 2005, 35, 971-976.	1.6	60
66	The Magnitude of Akt/Phosphatidylinositol 3â€²-Kinase Proliferating Signaling Is Related to CD45 Expression in Human Myeloma Cells. Journal of Immunology, 2004, 173, 4953-4959.	0.4	35
67	The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. European Journal of Immunology, 2004, 34, 3156-3164.	1.6	81
68	VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood, 2004, 104, 2886-2892.	0.6	147
69	Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells. Blood, 2002, 100, 194-199.	0.6	387
70	IL-6 UPREGULATES ITS OWN RECEPTOR ON SOME HUMAN MYELOMA CELL LINES. Cytokine, 2001, 14, 352-356.	1.4	27
71	Protein kinase C Î´ and Î· isoenzymes control the shedding of the interleukin 6 receptor Î± in myeloma cells. Biochemical Journal, 2001, 358, 193.	1.7	22
72	Protein kinase C Î´ and Î· isoenzymes control the shedding of the interleukin 6 receptor Î± in myeloma cells. Biochemical Journal, 2001, 358, 193-200.	1.7	32

#	Article	IF	Citations
73	Interferon Î± extends the survival of human myeloma cells through an upregulation of the Mcl-1 anti-apoptotic molecule. British Journal of Haematology, 2001, 112, 358-363.	1.2	44
74	SOLUBLE IL-6RÎ± UPREGULATES IL-6, MMP-1 AND MMP-2 SECRETION IN BONE MARROW STROMAL CELLS. Cytokine, 2000, 12, 1426-1429.	1.4	31
75	Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells. British Journal of Haematology, 1999, 107, 392-395.	1.2	136
76	IL-6 up-regulates Mcl-1 in human myeloma cells through JAKâ€‰/â€‰STAT rather than Rasâ€‰/â€‰MAP kinase pathway. European Journal of Immunology, 1999, 29, 3945-3950.	1.6	232
77	Metalloproteinases in Multiple Myeloma: Production of Matrix Metalloproteinase-9 (MMP-9), Activation of proMMP-2, and Induction of MMP-1 by Myeloma Cells. Blood, 1997, 90, 1649-1655.	0.6	167
78	The gp 130 family cytokines ILâ€6, LIF and OSM but not ILâ€11 can reverse the antiâ€proliferative effect of dexamethasone on human myeloma cells. British Journal of Haematology, 1995, 90, 707-710.	1.2	45
79	Intermolecular complexes between three human CD1 molecules on normal thymus cells. Immunogenetics, 1988, 27, 187-195.	1.2	19